New Kasr Al-Aini Teaching Hospital, Cairo University, Egypt.
Nephron Clin Pract. 2011;119(1):c41-9; discussion c49. doi: 10.1159/000324652. Epub 2011 Jun 15.
Epidemiological studies have shown a relationship between hepatitis B virus (HBV) infection and development of proteinuria in some patients (most commonly children), with a predominance for male gender and histological findings of membranous nephropathy on renal biopsy. The presence of immune complexes in the kidney suggests an immune complex basis for the disease, but a direct relation between HBV and membranous nephropathy (or other types of glomerular diseases) remains to be proven. Clearance of HBV antigens, either spontaneous or following antiviral treatments results in improvement in proteinuria. Thus, prompt recognition and specific antiviral treatment are critical in managing patients with HBV and renal involvement. The present review focuses on treatment of HBV with special emphasis given to antiviral therapies, its complications, and dosing in patients with HBV-associated kidney disease.
流行病学研究表明,乙型肝炎病毒(HBV)感染与一些患者(最常见于儿童)蛋白尿的发生有关,男性居多,肾活检表现为膜性肾病。肾脏中免疫复合物的存在提示疾病的免疫复合物基础,但 HBV 与膜性肾病(或其他类型的肾小球疾病)之间的直接关系仍有待证实。HBV 抗原的清除,无论是自发的还是抗病毒治疗后的,都可导致蛋白尿的改善。因此,及时识别和特定的抗病毒治疗对于 HBV 合并肾损害患者的治疗至关重要。本综述重点介绍 HBV 的治疗,特别强调抗病毒治疗及其并发症,以及 HBV 相关肾病患者的剂量。